Teva Pharmaceutical Industries expects to finalize an opioid settlement in the United States by year-end and start paying in 2023, its chief executive said on Sunday, while confirming he was unlikely to renew his contract next year.
https://www.pharmalive.com/wp-content/uploads/2022/09/ReutersTevaCEO9-19-2022.jpg8001200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-09-19 05:39:582022-09-19 10:36:18Teva expects to start paying U.S. opioid settlement in 2023